Neurooncology: 2022 update

Authors

  • Pieter Wesseling Department of Pathology, Amsterdam University Medical Centers/VUmc, Brain Tumor Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands; Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
  • Jacob S. Rozowsky Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands

DOI:

https://doi.org/10.17879/freeneuropathology-2022-3804

Keywords:

Brain tumor, Neuropathology, Molecular diagnostics, Glioblastoma, Medulloblastoma

Abstract

Abstract

This ‘Neurooncology: 2022 update’ presents topics that were selected by the authors as top ten discoveries published in 2021 in the broader field of neurooncological pathology. This time, the spectrum of topics includes: papers with a direct impact on daily diagnostic practice of CNS tumors in general and with information on how to improve grading of meningiomas; studies shedding new light on the oncogenesis of gliomas (in particular ‘optic gliomas’ and H3-mutant gliomas); several ‘multi-omic’ investigations unraveling the intra-tumoral heterogeneity of especially glioblastomas further; a study indicating the potential of ‘repurposing’ Prozac®; for the treatment of glioblastomas; liquid biopsy using CSF for assessment of residual medulloblastoma. In the last part of this review some other papers are mentioned that didn’t make it to this (quite subjective) top ten list.

Metrics

Metrics Loading ...

Downloads

Published

2022-02-24

How to Cite

Wesseling, P., & Rozowsky, J. S. (2022). Neurooncology: 2022 update. Free Neuropathology, 3, 4. https://doi.org/10.17879/freeneuropathology-2022-3804

Issue

Vol. 3 (2022)

Section

Reviews

License

Copyright (c) 2022 Pieter Wesseling, Jacob S. Rozowsky

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Papers are published open access under the Creative Commons BY 4.0 license. This license lets others distribute, remix, adapt, and build upon your work, even commercially, as long as they credit you for the original creation. Data included in the article are made available under the CC0 1.0 Public Domain Dedication waiver, unless otherwise stated, meaning that all copyrights are waived.